SLS - Latest News

SELLAS Life Sciences Group, Inc. (SLS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $1.59B. Beta to the broader market is 2.57.

The article list below shows the most recent SLS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent SLS Headlines

Sellas Life Sciences Stock Jumps on Trial Results Timeline

schaeffersresearch.com - Nov 13, 2026

Sellas Life Sciences Group Inc (NASDAQ:SLS) stock is up 7% to trade at $8. 59 after the biotech company announced that results from its closely watche

SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

globenewswire.com - Nov 12, 2026

- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report thi

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

globenewswire.com - Nov 4, 2026

− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previou

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

globenewswire.com - Oct 28, 2026

- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happened

defenseworld.net - Oct 18, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report)'s stock price fell 11.

How News Affects SLS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SLS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked SLS news questions

What is the latest SLS news headline?
The most recent SLS headline (Nov 13, 2026) is "Sellas Life Sciences Stock Jumps on Trial Results Timeline". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
How fresh is the SLS news on this page?
News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
What SLS news moves options pricing?
Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
How can I track unusual SLS options activity related to news?
Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.